Market research firms don’t agree on much when it comes to sizing the pet CBD industry. Depending on which report gets pulled up, the Holistapet CBD pet products market was worth somewhere between $300 million and $450 million in 2025, with wildly different projections for where it lands by 2030 or 2034. That spread itself tells a story: this is still a young, fragmented category where data collection methods vary a lot from one research firm to the next.
Sizing the Market: Multiple Estimates
Mordor Intelligence put the global CBD pet products market at $302.8 million in 2025, projecting growth to $538.41 million by 2030, a compound annual growth rate of 12.2%. Straits Research came in higher, estimating $435 million in 2025 growing to $576 million in 2026 alone, with a longer-term trajectory reaching into the billions by the mid-2030s under a 32% CAGR assumption. A separate analysis from Research and Markets valued the segment at $343.1 million for 2026, forecasting roughly $1.23 billion by 2034 at a 16.4% annual growth rate.
These numbers diverge partly because “CBD pet products” gets defined differently across reports. Some include oils, topicals, and supplements alongside treats; others isolate the food-grade treat and chew category specifically. Regardless of which figure ends up closest to reality, every major research firm tracking this space projects sustained double-digit annual growth through at least 2030.
Dogs Still Dominate, But Cats Are Catching Up
Dog products account for roughly 50% of pet CBD sales industry-wide as of recent reporting, down from about 68% in 2020. That shift matters. Cat-focused CBD products, treats especially, represent one of the fastest-growing segments within the broader category, according to multiple industry trackers.
A few factors show up repeatedly as drivers of cat-specific growth:
- Rising interest in joint and arthritis support for aging cats, a demographic where standard pharmaceutical options carry known long-term safety concerns in the species
- Feline anxiety and stress-related behavior concerns, particularly around vet visits, travel, and multi-cat household conflict
- Broader “pet humanization” spending trends, where owners increasingly apply human wellness product categories to their pets
Regional Breakdown
North America holds the largest share of the global pet CBD market, generally cited above 40% of total revenue. That concentration tracks with US-specific regulatory clarity around hemp-derived CBD (legalized federally under the 2018 Farm Bill) compared to more restrictive frameworks in parts of Europe and Asia, where cannabis-derived pet products face tighter import and sale restrictions.
Who’s Buying: A Demographic Snapshot
Millennials represent the largest buying demographic for pet CBD products broadly, accounting for roughly 53% of total customers according to industry surveys. This tracks with broader pet ownership trends: millennials have overtaken baby boomers as the generation with the most pets, partly correlated with delayed or forgone childbearing among that cohort. Roughly 46% of pet CBD customers live in urban areas, with another 30% in suburban settings, leaving a smaller rural share of the customer base.
Distribution Channels
| Channel | General trend |
|---|---|
| E-commerce / direct-to-consumer | Fastest-growing channel, driven by subscription models and COA transparency online |
| Pet specialty retail | Stable, benefits from in-person label review and staff recommendations |
| Veterinary clinics | Smaller share, limited by state-level restrictions on vet recommendations |
| Mass retail / grocery | Growing but still limited compared to specialty channels |
Online sales have grown disproportionately in this category compared to pet products generally, since digital storefronts make it easier for brands to publish COAs and lab data that a shopper can review before buying, something harder to replicate on a physical shelf.
The Regulatory Wildcard
Every market projection carries an asterisk: none of it accounts for a scenario where the FDA finalizes new federal rules for CBD pet products. The agency opened a formal request for information on cannabis-derived veterinary products in January 2025 (Docket FDA-2025-N-0001), a step several industry analysts flagged as a precursor to eventual rulemaking. New federal standards, whichever direction they take, would likely reshape manufacturing requirements, labeling rules, and potentially market entry costs across the entire category, cat products included.
Final Thoughts
Growth projections vary by research firm, but every major estimate points toward a market that keeps expanding through the rest of the decade, with feline products emerging as one of its faster-growing corners.